Pharmaceutical research and development services.;
Domain names similar "CABA"
News around "CABA" trademark
News sentiment analysis powered by sentiment-insight.com
2023-02-14
positive
Eversept Partners Now Owns 1.00% of Cabaletta Bio (CABA)
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies. The company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial. The put/call ratio of CABA is 0.26, indicating a bullish outlook.
2023-02-09
positive
Adage Capital Partners Gp, L.l.c. Increases Position in Cabaletta Bio (CABA)
Adage Capital Partners Gp, L.l.c. has filed a 13G/A form with the SEC disclosing ownership of 2.56MM shares of Cabaletta Bio Inc (CABA). This represents 9.99% of the company. Analyst Price Forecast Suggests 5.91% Upside as of February 9, 2023, the average one-year price target is $13.09.
2023-02-06
positive
Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy
Cabaletta Bio, Inc. (CABA) currently has a Momentum Style Score of B. Style Scores work as a complement to the Zacks Rank, our stock rating system. Shares of Cabaletta Bio have increased 417.23% over the past quarter and have gained 315.88% in the last year.
2023-01-31
positive
Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why
Cabaletta Bio, Inc. (CABA) is one of the several suitable candidates that passed through the screen. A price increase of 23.9% over the past four weeks ensures that the trend is still in place. CABA is currently trading at 93.6% of its 52-week High-Low Range.
2023-01-19
neutral
12 Biotech Stocks Hit New Highs; Did You Make The Most Of It?
Cabaletta Bio Inc. (CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Poseida Therapeutics Inc (STX) Poseida is advancing a new class of treatments for patients with cancer and rare diseases.
Sign Up
